Autopsy report · NCT04241068
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
Cause of deathFunding or business
“Sponsor's Decision”
Life of this trial
- Registered 1 month before it started.
- Ran for about 4 years 5 months before it stopped.
- 1,696 participants enrolled.
- Results were posted on the registry 7 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Biogen
- Sponsor type
- Industry
- Conditions
- Alzheimer's Disease
- Interventions
- Aducanumab
- Participants
- 1,696
- Sites
- 297
- Countries
- Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Japan, Netherlands, Poland and more
Trials that died the same way
- Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors
“Sponsor decision”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.